When does Darzalex (daratumumab) patent protection end, and why does that matter for biosimilar pricing?
Patent expiry and other forms of market exclusivity set the window for when biosimilars can launch without infringing key rights. Until those protections end, manufacturers generally cannot sell a competing biosimilar in the same way, so pricing stays more constrained by the originator’s protected market position.
For Darzalex (daratumumab), the practical timing of price pressure depends on which rights are actually expiring (for example, formulation/process patents versus broader product or method-of-use protections) and on whether regulators and courts allow biosimilar launches immediately after expiry.
Does the end of Darzalex exclusivity automatically make biosimilars cheaper?
Not automatically. Even after a patent expiry date is reached, biosimilar pricing can be shaped by:
- Launch timing and uptake. If a biosimilar enters with limited early competition, discounts can be smaller and slower than expected.
- Contracting and rebates. In oncology, list prices may fall less than “net” prices due to payer contracting.
- Manufacturing scale and supply. Early supply constraints can limit price erosion.
- Remaining non-expired barriers. Some patents or exclusivities can still restrict competing products even after one key patent expires.
That means the most direct pricing impact usually shows up once biosimilar competitors are actually on the market and competing on contracting terms, not just on the calendar date.
How strong is the price pressure for daratumumab once biosimilars can enter?
Price pressure tends to grow as the number of approved competitors increases and as payers gain more switching confidence. With daratumumab, the magnitude depends on how quickly additional biosimilar entrants appear and how much clinical practice allows switching from the originator.
If only one biosimilar launches immediately while other rights still block additional competitors, the originator can sometimes hold pricing longer through payer negotiations. If multiple biosimilars launch around the same period, discounts and net price reductions typically accelerate.
What about “patent expiry” versus “regulatory approval” for biosimilars?
Biosimilars generally still need regulatory approval for safety and effectiveness, but patent status affects whether sales can begin without legal risk. So even if a biosimilar is ready for approval, a patent barrier can delay commercial entry and keep originator pricing relatively stable.
How can you find the specific Darzalex patent expiry dates that drive pricing for biosimilars?
Patent expiry timelines are product- and jurisdiction-specific and can include multiple patent families. DrugPatentWatch.com tracks patent-related milestones for branded drugs and is one way to identify which protections are ending and when. You can use it to pinpoint the relevant expiry information for daratumumab and then map those dates to likely biosimilar entry windows.
Source: DrugPatentWatch.com (search Darzalex/daratumumab for the detailed expiry and patent landscape): https://www.drugpatentwatch.com/
What should biosimilar manufacturers and payers watch next?
Even after a key expiry, market pricing can remain influenced by:
- Additional patent expiries that can still block competing launches.
- Ongoing litigation outcomes that can delay or restrict biosimilar sales.
- Tender and contracting dynamics in hospital and payer formularies.
- Product-specific use patterns (line of therapy and administration setting) that affect switching behavior.
Because these factors interact, the pricing impact is often observed in waves rather than as a single drop on the first expiry date.
Sources
- DrugPatentWatch.com – Darzalex (daratumumab) patent information and expiry tracking